Canaccord Genuity Group Has Lowered Expectations for Intellia Therapeutics (NASDAQ:NTLA) Stock Price

Intellia Therapeutics (NASDAQ:NTLA) had its price target reduced by equities research analysts at Canaccord Genuity Group from $54.00 to $48.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Canaccord Genuity Group’s target price would suggest a potential upside of 247.32% from the stock’s previous close.

Several other brokerages have also recently issued reports on NTLA. Citizens Jmp increased their target price on shares of Intellia Therapeutics from $21.00 to $28.00 and gave the stock a “market outperform” rating in a report on Tuesday. Bank of America reaffirmed a “neutral” rating on shares of Intellia Therapeutics in a research report on Monday. JonesTrading lowered shares of Intellia Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, November 11th. Wall Street Zen downgraded shares of Intellia Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, January 18th. Finally, Oppenheimer set a $27.00 target price on Intellia Therapeutics in a report on Friday, November 7th. Eleven equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Intellia Therapeutics presently has an average rating of “Hold” and a consensus price target of $19.59.

Intellia Therapeutics Stock Up 1.6%

Shares of NASDAQ:NTLA opened at $13.82 on Tuesday. The business’s 50 day moving average is $12.17 and its 200 day moving average is $13.10. The stock has a market cap of $1.63 billion, a P/E ratio of -3.61 and a beta of 2.10. Intellia Therapeutics has a 52-week low of $5.90 and a 52-week high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Thursday, February 26th. The company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($0.99) by $0.16. The business had revenue of $23.02 million during the quarter, compared to analysts’ expectations of $12.17 million. Intellia Therapeutics had a negative return on equity of 56.81% and a negative net margin of 609.85%.The business’s revenue for the quarter was up 78.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.27) EPS. On average, sell-side analysts anticipate that Intellia Therapeutics will post -5.07 EPS for the current fiscal year.

Insider Transactions at Intellia Therapeutics

In other news, EVP Birgit C. Schultes sold 8,508 shares of the stock in a transaction on Monday, January 5th. The stock was sold at an average price of $9.21, for a total transaction of $78,358.68. Following the completion of the sale, the executive vice president owned 98,533 shares in the company, valued at approximately $907,488.93. This represents a 7.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP James Basta sold 10,397 shares of the business’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $95,756.37. Following the transaction, the executive vice president owned 101,528 shares in the company, valued at approximately $935,072.88. This trade represents a 9.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 53,051 shares of company stock valued at $488,600. Corporate insiders own 3.10% of the company’s stock.

Hedge Funds Weigh In On Intellia Therapeutics

Several hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC raised its position in shares of Intellia Therapeutics by 154.1% in the 1st quarter. AQR Capital Management LLC now owns 90,875 shares of the company’s stock valued at $646,000 after purchasing an additional 55,118 shares during the last quarter. Woodline Partners LP purchased a new position in shares of Intellia Therapeutics in the first quarter worth $171,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Intellia Therapeutics by 8.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 521,706 shares of the company’s stock worth $3,709,000 after buying an additional 38,521 shares during the period. Atria Investments Inc acquired a new stake in shares of Intellia Therapeutics during the second quarter worth $96,000. Finally, Intellectus Partners LLC grew its holdings in shares of Intellia Therapeutics by 3.8% during the second quarter. Intellectus Partners LLC now owns 85,975 shares of the company’s stock valued at $806,000 after buying an additional 3,150 shares during the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Trending Headlines about Intellia Therapeutics

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: FDA lifts clinical holds / allows second in‑human trial to resume, removing a major regulatory overhang and clearing Intellia to restart an important gene‑editing program. Read More. Read More.
• Positive Sentiment: Multiple analyst upgrades and target increases (JonesTrading to Buy, Leerink & HC Wainwright bumping targets, William Blair upgrade to Outperform) have supported sentiment and likely drove buying interest. JonesTrading set a $29 PT; HC Wainwright raised its PT to $30. Read More. Read More.
• Positive Sentiment: Intellia presented longer‑term clinical data for lonvoguran (lonvo‑z) at AAAAI showing multi‑year follow‑up after a one‑time dose — reinforces the durability narrative for a key therapeutic candidate. Read More.
• Positive Sentiment: High‑profile investor interest: Cathie Wood’s Ark (coverage piece) noted buying activity in beaten‑up growth names, including Intellia — a potential source of additional demand from momentum/growth investors. Read More.
• Neutral Sentiment: Other broker moves mixed: RBC, Wells Fargo and others nudged targets modestly higher (to ~$15), while Canaccord cut its target from $54 to $48 — consensus remains wide, reflecting varying views on timelines and commercialization risk. Read More.
• Negative Sentiment: HC Wainwright trimmed near‑term EPS estimates across several 2026 quarters and lowered full‑year forecasts slightly even while maintaining a Buy and a $30 PT — a reminder analysts expect continued cash burn and negative earnings into 2026. This raises execution risk and could limit multiple expansion. Read More.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.